PMID- 23114424
OWN - NLM
STAT- MEDLINE
DCOM- 20130513
LR  - 20211021
IS  - 2092-6413 (Electronic)
IS  - 1226-3613 (Print)
IS  - 1226-3613 (Linking)
VI  - 44
IP  - 11
DP  - 2012 Nov 30
TI  - Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance 
      and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term 
      diabetes.
PG  - 665-73
LID - 10.3858/emm.2012.44.11.075 [doi]
AB  - This study aimed to determine whether taurine supplementation improves metabolic 
      disturbances and diabetic complications in an animal model for type 2 diabetes. 
      We investigated whether taurine has therapeutic effects on glucose metabolism, 
      lipid metabolism, and diabetic complications in Otsuka Long- Evans Tokushima 
      fatty (OLETF) rats with long-term duration of diabetes. Fourteen 50-week-old 
      OLETF rats with chronic diabetes were fed a diet supplemented with taurine (2%) 
      or a non-supplemented control diet for 12 weeks. Taurine reduced blood glucose 
      levels over 12 weeks, and improved OGTT outcomes at 6 weeks after taurine 
      supplementation, in OLETF rats. Taurine significantly reduced insulin resistance 
      but did not improve beta-cell function or islet mass. After 12 weeks, taurine 
      significantly decreased serum levels of lipids such as triglyceride, cholesterol, 
      high density lipoprotein cholesterol, and low density lipoprotein cholesterol. 
      Taurine significantly reduced serum leptin, but not adiponectin levels. However, 
      taurine had no therapeutic effect on damaged tissues. Taurine ameliorated 
      hyperglycemia and dyslipidemia, at least in part, by improving insulin 
      sensitivity and leptin modulation in OLETF rats with long-term diabetes. 
      Additional study is needed to investigate whether taurine has the same beneficial 
      effects in human diabetic patients.
FAU - Kim, Kyoung Soo
AU  - Kim KS
AD  - East-West Bone and Joint Research Institute, Kyung Hee University Hospital at 
      Gangdong, Korea. labrea46@yahoo.co.kr
FAU - Oh, Da Hee
AU  - Oh DH
FAU - Kim, Jung Yeon
AU  - Kim JY
FAU - Lee, Bong Gn
AU  - Lee BG
FAU - You, Jeong Soon
AU  - You JS
FAU - Chang, Kyung Ja
AU  - Chang KJ
FAU - Chung, Hyun Ju
AU  - Chung HJ
FAU - Yoo, Myung Chul
AU  - Yoo MC
FAU - Yang, Hyung In
AU  - Yang HI
FAU - Kang, Ja Heon
AU  - Kang JH
FAU - Hwang, Yoo Chul
AU  - Hwang YC
FAU - Ahn, Kue Jeong
AU  - Ahn KJ
FAU - Chung, Ho Yeon
AU  - Chung HY
FAU - Jeong, In Kyung
AU  - Jeong IK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Exp Mol Med
JT  - Experimental & molecular medicine
JID - 9607880
RN  - 0 (Adipokines)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Leptin)
RN  - 0 (Lipids)
RN  - 1EQV5MLY3D (Taurine)
SB  - IM
MH  - Adipokines/blood
MH  - Animals
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Dietary Supplements
MH  - Dyslipidemias/blood/*drug therapy
MH  - Glucose Tolerance Test
MH  - Hyperglycemia/blood/*drug therapy
MH  - Hypoglycemic Agents/administration & dosage/*pharmacology
MH  - Hypolipidemic Agents/administration & dosage/*pharmacology
MH  - Insulin/metabolism/physiology
MH  - Insulin Resistance
MH  - Insulin Secretion
MH  - Insulin-Secreting Cells/metabolism/physiology
MH  - Leptin/*blood
MH  - Lipid Metabolism/drug effects
MH  - Lipids/blood
MH  - Male
MH  - Organ Specificity
MH  - Rats
MH  - Rats, Long-Evans
MH  - Taurine/administration & dosage/*pharmacology
PMC - PMC3509183
COIS- The authors declare that they have no competing interests.
EDAT- 2012/11/02 06:00
MHDA- 2013/05/15 06:00
PMCR- 2012/11/30
CRDT- 2012/11/02 06:00
PHST- 2012/11/02 06:00 [entrez]
PHST- 2012/11/02 06:00 [pubmed]
PHST- 2013/05/15 06:00 [medline]
PHST- 2012/11/30 00:00 [pmc-release]
AID - emm.2012.44.075 [pii]
AID - 10.3858/emm.2012.44.11.075 [doi]
PST - ppublish
SO  - Exp Mol Med. 2012 Nov 30;44(11):665-73. doi: 10.3858/emm.2012.44.11.075.